| Title |
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
|
|---|---|
| Published in |
Clinical Pharmacokinetics, December 2013
|
| DOI | 10.1007/s40262-013-0125-y |
| Pubmed ID | |
| Authors |
Fabrice Balavoine, Michel Azizi, Damien Bergerot, Nadia De Mota, Rémi Patouret, Bernard P. Roques, Catherine Llorens-Cortes |
| Abstract |
Inhibition of brain aminopeptidase A (APA), which converts angiotensin II into angiotensin III, has emerged as a novel antihypertensive treatment, as demonstrated in several experimental animal models. QGC001 (originally named RB150) is a prodrug of the specific and selective APA inhibitor EC33, and as such it is the prototype of a new class of centrally acting antihypertensive agents. Given by the oral route in hypertensive rats, it enters the brain and generates EC33, which blocks the brain renin-angiotensin system activity and normalises blood pressure. The aim of the present study was to evaluate the safety, pharmacokinetics and pharmacodynamic effects of QGC001 in humans. |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 38 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 13% |
| Researcher | 5 | 13% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Other | 3 | 8% |
| Unknown | 16 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 23% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Nursing and Health Professions | 2 | 5% |
| Psychology | 2 | 5% |
| Business, Management and Accounting | 1 | 3% |
| Other | 5 | 13% |
| Unknown | 17 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2017.
All research outputs
#3,774,772
of 22,745,803 outputs
Outputs from Clinical Pharmacokinetics
#215
of 1,481 outputs
Outputs of similar age
#45,363
of 307,388 outputs
Outputs of similar age from Clinical Pharmacokinetics
#1
of 8 outputs
Altmetric has tracked 22,745,803 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,481 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,388 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them